|
EIF4H expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.1644999999838E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.95710000000715E-06 |
| Normal-vs-Stage2 |
1.588630E-01 |
| Normal-vs-Stage3 |
4.59999999979921E-07 |
| Normal-vs-Stage4 |
6.74559999969127E-07 |
| Stage1-vs-Stage2 |
5.754400E-02 |
| Stage1-vs-Stage3 |
1.062390E-01 |
| Stage1-vs-Stage4 |
9.339900E-02 |
| Stage2-vs-Stage3 |
4.224700E-03 |
| Stage2-vs-Stage4 |
7.076300E-03 |
| Stage3-vs-Stage4 |
8.912200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.78369999945549E-07 |
| Normal-vs-AfricanAmerican |
2.584200E-02 |
| Normal-vs-Asian |
7.92259999999878E-05 |
| Caucasian-vs-AfricanAmerican |
3.378200E-01 |
| Caucasian-vs-Asian |
9.467600E-01 |
| AfricanAmerican-vs-Asian |
3.695600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.31339999999802E-05 |
| Normal-vs-Female |
2.20630000002942E-06 |
| Male-vs-Female |
9.897800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.65724999999783E-05 |
| Normal-vs-Age(41-60Yrs) |
3.86880000000644E-05 |
| Normal-vs-Age(61-80Yrs) |
1.57283999999702E-05 |
| Normal-vs-Age(81-100Yrs) |
2.761900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.821200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.269400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.784800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.231400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.904400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.763600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.702400E-03 |
| Classical-VS-Follicular |
3.972400E-01 |
| Classical-VS-Other |
1.574620E-01 |
| Classical-VS-Normal |
3.68719999999101E-06 |
| Tall-VS-Follicular |
4.644700E-03 |
| Tall-VS-Other |
9.528000E-01 |
| Tall-VS-Normal |
8.03279999961326E-07 |
| Follicular-VS-Other |
1.844040E-01 |
| Follicular-VS-Normal |
9.723600E-03 |
| Other-VS-Normal |
4.324500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.3923999999993E-05 |
| Normal-vs-N1 |
2.90649999623582E-08 |
| N0-vs-N1 |
6.684700E-03 |
|
|
